Increasing of FKBP9 can predict poor prognosis in patients with prostate cancer
ConclusionsFKBP9 may be a cancer promoter that enhances PCa progression, and the level of FKBP9 may be used as an independent precursor of PCa patients.
In conclusion, NKX3.1 shows routine expression in Sertoli cells and P501S shows routine expression in Leydig cells and rete testis epithelium. In addition, these markers can be positive in sex cord-stromal tumors and rete testis adenocarcinoma.
CONCLUSIONS: Neither a diagnosis of prostate cancer nor ADT use was associated with odds of MCI in this cross-sectional population-based study. PMID: 31821185 [PubMed - as supplied by publisher]
Correction to: In the original publication of the article, the values in the columns “Gleason Score” and “Clinical Stage” under the section Urologic Organization.
Condition: Prostate Cancer Interventions: Drug: Niraparib; Drug: Leuprolide; Drug: Abiraterone Acetate; Radiation: Stereotactic body radiotherapy (SBRT) Sponsors: University of Michigan Rogel Cancer Center; Janssen Scientific Affairs, LLC Not yet recruiting
PROSTATE cancer is the most common cancer in men in the UK and treatment outcomes depend greatly on how early it is caught. The warning signs associated with the disease are associated with the bladder and men who experience a certain issue in cold weather should not rule out the disease.
Short-term exercise may help reduce the adverse side effects of hormone therapy for patients with prostate cancer, according to a study published in theBritish Journal of Urology International (BJUI).Science Daily
Authors: Chen YF, Liang YX, Yang JA, Yuan DZ, Li J, Zheng SS, Wan YP, Wang B, Han ZD, Zhong WD Abstract Abnormal expression of Holliday junction recognition protein (HJURP) in several types of tumor cells plays a vital role in the formation and progression of tumors. Few studies have investigated the role of HJURP in prostate cancer (PCa). The aim of this study was to analyze the expression levels of HJURP in PCa and to establish the association with clinicopathological data. Reverse transcription quantitative polymerase chain reaction and immunohistochemical analysis were used to detect the expression levels of HJ...
Conclusion: Enzalutamide can be used to effectively treat mCRPC patients in daily clinical settings, despite the patients being older and less healthy than those enrolled in the previous randomised, clinical registration studies. PMID: 31815592 [PubMed - in process]
Prostate Cancer and Prostatic Diseases, Published online: 11 December 2019; doi:10.1038/s41391-019-0196-4Transperineal laser ablation for percutaneous treatment of benign prostatic hyperplasia: a feasibility study. Results at 6 and 12 months from a retrospective multi-centric study